Neuralink will have 100+ patients with functional thought-controlled computing by end of 2027

Neuralink has moved from first-in-human to ~20 patients in roughly 18 months, with international expansion to the UK and UAE underway. FDA breakthrough device designation validates the regulatory pathway. The question is no longer whether intracortical BCI works but whether it can scale from research to clinical infrastructure.

Confidence: 5/10 Supporting evidence:

• ~20 PRIME patients currently implanted with thought-controlled computing Evidence: strong (Neuralink PRIME)
• International expansion to UK and UAE indicates regulatory momentum Evidence: moderate (Neuralink PRIME)
• FDA breakthrough device designation validates pathway Evidence: strong (Neuralink PRIME)

Challenging evidence:

• Going from ~20 to 100+ requires 5x scaling of surgical infrastructure in 18 months
• Long-term (5-10 year) electrode biocompatibility is unproven — could limit patient pool
• Each surgery requires specialized neurosurgical teams — not a bottleneck that scales easily
• Cost per implant at research stage is prohibitive for most patients
• Standardized outcome measures across BCI trials do not yet exist
• Regulatory approval in UK/UAE does not guarantee patient volume

Evolution:

• Apr 5, 2026 — Initial thesis at 5/10. The trajectory from 0 to ~20 is encouraging, but surgical scaling is fundamentally different from software scaling. 100+ by end of 2027 requires roughly 4-5 implants per month, which demands multiple surgical centers operating in parallel. Achievable if Neuralink prioritizes it, but not certain.

Depends on: invasive-vs-noninvasive-bci, neuroprosthetics Would change if: Neuralink announces a multi-center surgical expansion, or if electrode degradation issues emerge in early patients.

---